DocWire News Editors

DocwireNews

To date, 41 states and Puerto Rico have laws for biosimilars. However, federal and state regulations on biosimilars are confusing, incomplete, and often discourage adoption, according to a presentation by&nbsp;Reginia Benjamin, BS, JD,&nbsp;director of legislative affairs at AMCP, and&nbsp;Edward Li, PharmD, MPH, BCOP,&nbsp;professor at the University of New England College of Pharmacy in Maine, at AMCP Annual Meeting 2018. They discussed recent developments regarding these therapies.State legislative language around biosimilars include:<ul>
<li>Required notice to the patient prior to dispensing, with a time frame that ranges from 24 hours to five years;</li>
<li>Additional labeling requirements and retention timeframes;</li>
<li>Approval by the patient prior to dispensing;</li>
<li>State Board of Pharmacy must maintain information its website of U.S. Food and Drug Administration (FDA)-approved interchangeable biosimilars; and</li>
<li>A pharmacist who selects an equivalent drug product or interchangeable biologic assumes no greater liability than would be incurred in filling a prescription for a reference agent.</li>
</ul>On the federal level, the Biosimilar User Fee Act (BsUFA) Reauthorization was signed into law in 2017 (BsUFA II) and requires the FDA to review and act on 90% of original biosimilar biologic applications within 10 months of the 60-day filing date. This is intended to allow for more communication across the entire application cycle. Under BsUFA II, an independent fee structure is established for biosimilars, increasing from $22 million in 2017 to $87 million in 2018 to ease the workload of the FDA in reviewing these agents.Patent litigation and settlement agreements are delaying significant market launches of many agents until 2022 and 2023. But, Dr. Li said, that improvements within BsUFA are likely to help speed the approval of these agents.Data from Europe are showing that biosimilars have led to decreased costs and increased access to biologics. In the United States, concerns remain that need to be addressed, such as clarity and support for switching and an understanding of off-label use.Education and stakeholder engagement are essential to the successful adoption of these agents. The Biosimilar Resource Center (<a href="https://www.biosimilarsresourcecenter.org/">biosimilarsresourcecenter.org/</a>) provides educational resources in a policy-neutral and non-promotional manner.Presentation L7: A Biosimilars Update: Regulation and Legislation. AMCP Annual Meeting 2018.

BMI Modifies the Relationship Between Glycemic Status and Asthma Severity in Children

Asthma

Jordana Jampel

Cutaneous Melanoma: Sun Protection Behaviors and UV Exposure in Canada

Melanoma

Leah Lawrence

Significant Cardiac Benefit Seen With Ifetroban in Patients With Duchenne Muscular Dystrophy

Neurology

Latest News

Updates in Biosimilar Legislation and Regulation

AMCP 2018

To date, 41 states and Puerto Rico have laws for biosimilars. However, federal and state regulations on biosimilars are confusing, incomplete, and often discourage adoption, ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe